Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 3, Number 5 **May 2004**

Articles

contents continued

Minireview

On the Cover

The novel estrogen analog 17α-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10), 20-tetraene-3,17β-diol ($APVE_2$) is shown minimized within the ligand binding pocket of both estrogen-receptor subtypes alpha (1ERE, *blue*) and beta (1QKM, *orange*). This molecule was chosen from a small library of 17α-modified-E_2 analogues originally designed for ER-β specificity. In a competition binding assay, $APVE_2$ was shown to exhibit moderate yet selective binding to ERβ. For details, see Mobley *et al.* in this issue.

Molecular Cancer Therapeutics is abstracted or indexed in Chemical Abstracts, Index Medicus, MEDLINE, BIOSIS Previews, and Current Contents. *Molecular Cancer Therapeutics* is also published online. Please visit http://mct.aacrjournals.org.